


SARS-CoV-2 Reporter Virus Particles

Integral Molecular's SARS-CoV-2 Reporter Virus Particles (RVPs) are replication-incompetent pseudotyped virus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation. SARS-CoV-2 RVPs display antigenically correct spike protein on a heterologous virus core and carry a modified genome that expresses a convenient optical reporter gene (GFP or luciferase) within 24 hours of cellular infection.

SARS-CoV-2 RVPs are available as a ready-to-use reagent that provides a safe and efficient alternative to plaque assays, and are produced under quality-controlled conditions as a critical reagent to enable regulatory submissions.


Advantages of SARS-CoV-2 RVPs

- Safe in a BSL-2 environment
- Quantitative (luciferase) or fluorescent (GFP) read-out
- Compatible with high-throughput plate-based assays
- Quality-controlled production for use as a critical reagent



- Antibody neutralization
- Serum screening
- High-throughput assays

Neutralization of SARS-CoV-2 RVPs



COVID-19 patient sera and a monoclonal antibody neutralize the infectivity of SARS-CoV-2 RVPs in a concentration-dependent fashion. The 10x MAb dilution here represents 10 µg/mL.

Catalog of 70+ RVP Variants

SARS-CoV-2 RVP Variant	Cat. No
Delta	RVP-763
Omicron (BA.1, BA.2, BA.4/BA.5)	RVP-768, 770, 774
Reference (Wuhan-Hu-1, D614G)	RVP-701, 702
Negative Control RVPs (VSV)	RVP-1002

Visit our [website](#) for the full listing of emerging RVP variants.
Additional strains/custom variants are available upon request.

Additional RVPs

Virus	Cat. No
Influenza A Virus	RVP-1201
Influenza B Virus	RVP-1301, 1303
Filoviruses (Ebola, Marburg)	RVP-1401, 1501
Dengue Virus Serotypes 1-4	RVP-101, 201, 301, 401
Zika Virus	RVP-601

With two decades of virology experience, Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials.



OUR MISSION

Founded in 2001, Integral Molecular's mission is to develop and apply innovative technologies that advance therapeutic discovery against difficult protein targets including viral proteins.

WHY WORK WITH US

Deep expertise in virology is at the core of Integral Molecular's 20-year history. Our technologies and R&D services enable over 400 companies working in vaccine research and drug discovery and have been published in over 350 peer-review publications including in *Cell*, *Science*, and *Nature*.

Over the past 10 years, scientists at Integral Molecular have been on the forefront of combatting viral epidemics such as Zika, Ebola, and Chikungunya, in addition to working on dengue, HIV, RSV, Hepatitis C, Hepatitis B, Equine Encephalitis, and influenza viruses.

20+

YEARS VIROLOGY EXPERIENCE

85+

REPORTER VIRUSES & VARIANTS

TRUSTED BY


100+

VIROLOGY LABORATORIES

CONTRIBUTIONS


200+

TO VIROLOGY PUBLICATIONS




Virology

The most comprehensive catalog of Reporter Virus Particles, including SARS-CoV-2, dengue, Zika, and influenza



Epitope Mapping

Conformational, high-resolution mapping to characterize antiviral antibodies, help predict viral escape and optimize MAb cocktails




MAb Specificity Profiling

The largest array of membrane proteins for *in vitro* safety & specificity profiling of antibody-based therapeutics



Lipoparticles

Virus-like particles with high-concentration, native proteins for immunization and screening



MPS Antibody Discovery

MAbs against highly conserved, structurally complex membrane proteins delivered with >95% success

